Zhang Xiaoman, Liu Dequan, Yin Sulan, Gao Yaru, Li Xiaorui, Wu Guangzhen
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Laboratory Medicine, The Faculty of Medicine and Pharmaceutical Sciences, Hainan Vocational University of Science and Technology, Haikou, China.
Front Endocrinol (Lausanne). 2025 Jul 25;16:1530578. doi: 10.3389/fendo.2025.1530578. eCollection 2025.
Epigenetic changes, such as DNA methylation, chromatin remodeling, and histone modifications, regulate gene expression without altering the DNA sequence. This review systematically analyzed over 500 studies including human cell line experiments (n>200), animal models (n>50), clinical cohort studies (n>100), and bioinformatics analyses retrieved from PubMed, Web of Science, and TCGA (The Cancer Genome Atlas). Studies increasingly show that genes involved in glucose and lipid metabolism, energy production, and modulation of metabolic hormones are regulated through epigenetic mechanisms. On the other hand, various metabolites participate in epigenetic modifications as coenzymes or substrates. Therefore, a greater understanding of the crosstalk between metabolism and epigenetics in cancer-related pathways could lead to the identification of key signaling molecules for targeted therapies, and raise the possibility of using dietary interventions to modulate epigenetic markers for individualized treatment. In this review, we have summarized the metabolic and epigenetic regulatory networks in cancer development, including glycolipid metabolic reprograming, the role of metabolites produced by the glut flora and tumor microenvironment, and key epigenetic drivers such as non-coding RNAs (ncRNAs). Data were curated from peer-reviewed articles, grounded in mechanistic studies using cell lines (SW480, MCF7 (Michigan cancer foundation-7)) and animal models (APC-mutant mice), with a focus on mechanistic studies, omics analyses, and translational research. Furthermore, we have discussed the potential of therapeutically targeting these pathways, along with the current challenges and future research directions, and a new strategy for reversing therapeutic drug resistance based on metabolism and epigenetic interaction was systematically explored.
表观遗传变化,如DNA甲基化、染色质重塑和组蛋白修饰,在不改变DNA序列的情况下调节基因表达。本综述系统分析了500多项研究,包括人类细胞系实验(n>200)、动物模型(n>50)、临床队列研究(n>100),以及从PubMed、科学网和癌症基因组图谱(TCGA)检索到的生物信息学分析。研究越来越表明,参与葡萄糖和脂质代谢、能量产生以及代谢激素调节的基因是通过表观遗传机制调控的。另一方面,各种代谢物作为辅酶或底物参与表观遗传修饰。因此,更深入了解癌症相关途径中代谢与表观遗传学之间的相互作用,可能会识别出用于靶向治疗的关键信号分子,并增加利用饮食干预来调节表观遗传标记以实现个体化治疗的可能性。在本综述中,我们总结了癌症发展过程中的代谢和表观遗传调控网络,包括糖脂代谢重编程、肠道菌群和肿瘤微环境产生的代谢物的作用,以及非编码RNA(ncRNA)等关键表观遗传驱动因素。数据来自同行评审的文章,基于使用细胞系(SW480、MCF7(密歇根癌症基金会-7))和动物模型(APC突变小鼠)的机制研究,重点是机制研究、组学分析和转化研究。此外,我们还讨论了靶向这些途径的治疗潜力,以及当前的挑战和未来的研究方向,并系统探索了一种基于代谢和表观遗传相互作用逆转治疗耐药性的新策略。